Healing of active, non-atrophic autoimmune gastritis by H. pylori eradication

Digestion

Volumn 64, Issue 1, 2001, Pages 30-39

  Muller H ^a   Rappel, S ^a   Wundisch T ^a   Bayerdorffer E ^a   Stolte, M ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

Autoimmune gastritis; Helicobacter pylori

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; ANTI ULCER AGENTS; ANTIBIOTIC AGENT; ANTIULCER AGENT; PROTON PUMP;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL COLONIZATION; DISEASE ACTIVITY; ERADICATION THERAPY; FEMALE; GASTRITIS; GRAM NEGATIVE INFECTION; HEALING; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; DRUG EFFECT; HELICOBACTER INFECTION; ISOLATION AND PURIFICATION; MICROBIOLOGY; RETROSPECTIVE STUDY; STOMACH MUCOSA; TREATMENT OUTCOME; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-ULCER AGENTS; ANTIBIOTICS, COMBINED; AUTOIMMUNE DISEASES; CLARITHROMYCIN; FEMALE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; MALE; METRONIDAZOLE; MIDDLE AGE; PROTON PUMPS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WOUND HEALING;

EID: 0034830931     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048836     Document Type: Article

References (38)

1. Prognosis of gastric carcinoid tumors
2. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study
3. Gastric carcinoids and neuroendocrine carcinomas: Pathogenesis, pathology and behavior
4. Revised classification of neuroendocrine tumors of the lung, pancreas and gut
5. Surveillance of pernicious anemia
6. A reappraisal of the nature and significance of chronic atrophic gastritis
7. Active autoimmune gastritis without total atrophy of the glands
8. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis
9. Antigastric autoantibodies in Helicobacter pylori gastritis: Prevalence, in-situ binding sites and clues for clinical relevances
10. Antigastric autoantibodies in Helicobacter pylori infection: Implications of histological and clinical parameters of gastritis
11. Bugs on trial: The cause of Helicobacter pylori and autoimmunity
12. Parietal cell antibodies in pernicious anemia inhibit H(+),K(+)-adenosine triphosphate, the proton pump of the stomach
13. The H(+),K(+)-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy
14. Evidence of novel pathways for the formation of antigastric autoantibodies in Helicobacter pylori gastritis
15. Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male
16. Eradication of Helicobacter pylori heals atrophic corpus gastritis caused by long-term treatment with omeprazole
17. Significant improvement of atrophy after eradication therapy in atrophic body gastritis
18. Classification and grading of gastritis. The updated Sydney System
19. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis
20. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study
21. Pernicious anemia and Campylobacter-like organisms: Is the gastric antrum resistant to colonisation?
22. Influence of omeprazole on urease activity of Helicobacter pylori in vitro
23. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds
24. Intragastric bacterial activity and nitrosation before, during and after treatment with omeprazole
25. Effect of curing Helicobacter pylori infection on intra-gastric pH during treatment with omeprazole
26. The effect of environmental pH on proton motive force of Helicobacter pylori
27. Elimination ofHelicobacter pylori under treatment with omeprazole
28. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole
29. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus under 12 months of treatment with omeprazole and lanzoprazole
30. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk for argyrophil cell hyperplasia
31. Minimal chronic inactive gastritis: Indicator of pre-existing Helicobacter pylori gastritis?
32. Effect of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients
33. Omeprazole-induced pseudohypertrophy of gastric parietal cells
34. Helicobacter pylori infection and chronic gastric acid hyposecretion
35. Effect of Helicobacter pylori eradication on gastritis in relation to CagA: A prospective 1-year follow-up study
36. Do intestinal metaplasia and gastric atrophy reverse after Helicobacter pylori eradication?
37. Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis
38. Atrophic body gastritis: Distinct features associated with Helicobacter pylori infection